News J&J to buy US biotech Taris and its bladder cancer drug devi... Johnson & Johnson is to buy the privately-owned biotech Taris, and a device that can deliver cancer drugs to the bladder.
News BeiGene's Brukinsa fails to beat AbbVie/J&J's Ibrutinib in W... BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).
Events Partner Content 13th Annual Pharma Resource Planning and Portfolio Managemen... Prioritizing Projects with Tools, Data, and Governance
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
